Australia's Eve Investments climb on diabetes drink launch

Eve Health

11/10/2021 03:19

** Shares of Eve Investments Ltd  EVE.AX  rise as much as
14.3% to A$0.004, on track for their best day since Sept. 30
    ** The health and wellness co reports that launch of Omni-D,
a diabetes pre-meal drink, is underway, as per the new licence
deal between Omni Innovation (owned 38% by EVE) and Australia
based biotech co Myopharm Ltd  urn:newsml:reuters.com:*:nASXzQQlz
    ** Adds that Omni's pre-meal glycaemic product reduces blood
glucose spike which normally occurs after eating a standard meal
    ** In Australia, about 1 mln people live with Type 2
diabetes and another 2 mln live with pre-diabetes - EVE
    ** Co says it is exploring licensing deals in the U.S. and
India where a large population live with diabetes
    ** Stock down 61.1% YTD, as of last close 
    





 (Reporting by Jaskiran Singh in Bengaluru)
 ((jaskiran.singh@thomsonreuters.com))